Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

Shots: Nuformix is eligible to receive an up front, development milestone along with royalties when the net sales reaching $2.76M/annum Oxilio gets an exclusive license to research, develop and commercialize NXP001 globally for oncology indications. The agreement allows Oxilio to focus on developing a unique formulation and dosage form with NXP001 to progress into the …

Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease Read More »